A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondylitis

Celgene Corporation0 个研究点目标入组 456 人开始时间: 2012年5月29日最近更新: 2019年2月28日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Celgene Corporation
入组人数: 456

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•1. Males or females, = 18 years of age at the time of signing the informed consent document.
•2. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
•3. Able to adhere to the study visit schedule and other protocol requirements.
•4. Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met:
•a.Radiographic criteria (at least 1), documented by the central reader before the subject is randomized
•b. Clinical criteria (at least 1), documented in physical examination
•5. Must have symptoms of active axial disease at screening and baseline (at time of randomization), as determined by a BASDAI NRS score of = 4 and a total back pain NRS score = 4.
•6. Must be receiving treatment on an outpatient basis.
•7. Must be in good health (except for AS) as judged by the Investigator, based on medical history, physical examination, 12-lead ECG, chest radiograph, clinical laboratories and urinalysis.
•8. Must agree to maintain the same stable dose of medication (or lack of medication) taken for AS prior to randomization through Week 24 of the study as described below. Change in medication may be allowed for safety reasons.
•a. Analgesics must be stable for at least 14 days prior to Day 0
•b. Disease-modifying anti-rheumatic drugs (DMARDs) must have been taken for at least 16 weeks and must be stable for at least 28 days prior to Day 0
•c. Corticosteroids must be stable for at least 28 days prior to Day 0.
•9. Must meet the following laboratory criteria at screening:
•a. White blood cell count = 3000/mm3 (= 3.0 x 109/L) and < 14,000/mm3 (< 14 x 109/L)
•b. Platelet count = 100,000/µL (= 100 x 109/L)
•c. Serum creatinine = 1.5 mg/dL (= 132.6 µmol/L)
•d. AST (SGOT) and ALT (SGPT) = 2 x upper limit of normal (ULN). If initial test shows ALT or AST > 2 times the ULN, one repeat test is allowed during the screening period.
•e. Total bilirubin = 2 mg/dL (= 34 µmol/L). If initial test result is > 2 mg/dL, one repeat test is allowed during the screening period.
•f. Hemoglobin = 9 g/dL (= 5.6 mmol/L)
•g. Hemoglobin A1c = 9.0%
•h. Negative for hepatitis B surface antigen
•i. Negative for hepatitis C antibody
•10. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraception options described below:
•Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal liga

排除标准

•1. Major surgery (including spinal surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
•2. Autoimmune diseases such as, but not limited to: systemic lupus erythematosus, mixed connective tissue disease, multiple sclerosis, or scleroderma.
•3. Prior history of, or current, inflammatory joint disease other than AS (eg, rheumatoid arthritis, gout, reactive arthritis, psoriatic arthritis, Lyme disease).
•4. Uncontrolled, severe psoriasis (defined as Body Surface Area > 10%) or active inflammatory bowel disease (Crohn’s disease or ulcerative colitis) based on an unequivocal positive calprotectin stool test defined by the local or central lab reference values.
•5. Uncontrolled uveitis at the time of randomization. Asymptomatic, concurrently treated and controlled uveitis is acceptable at randomization, as long as the treatment is limited to topical ophthalmic therapy and/or intra-ocular injections of corticosteroids. Subjects are allowed to be initiated with these therapies during screening, continue on them through randomization and tapered off or discontinue these therapies while on study as medically appropriate. Systemic treatment for uveitis is not allowed, and would result in discontinuation from the study.
•6. Prior treatment with a TNF blocker or any biologic treatment for AS.
•7. If discontinuing treatment of DMARD, then adequate washout is required prior to randomization.
•8. Treatment with any investigational agent within four weeks (or five half-lives of the investigational drug, whichever is longer) of screening.
•9. Intra-articular or parenteral corticosteroids are not allowed within 6 weeks prior to randomization.
•10. Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
•11. Pregnant women or nursing (breast-feeding) mothers.
•12. Evidence of serious, poorly controlled concomitant cardiovascular, nervous system, pulmonary (including severe chronic obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus as defined by HbA1c > 9.0%) or gastrointestinal (GI) disease.
•13. Poorly controlled disease states, such as asthma, where flares are commonly treated with oral or parenteral corticosteroids.
•14. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, histoplasmosis, coccidiomycosis, but excluding onychomycosis) or any major episode of infection requiring hospitalization or treatment with IV or oral antibiotics within 4 weeks of screening.
•15. History of positive test for, or any clinical suspicion of human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
•16. History of malignancy, including solid tumors and hematologic malignancies (except basal cell carcinoma of the skin that has been excised and cured).
•17. History of alcohol, drug or chemical abuse within the 6 months prior to screening.
•18. Any significant medical condition or laboratory abnormali

研究者

发起方

Celgene Corporation

相似试验

进行中（未招募）

1 期

Study of the efficacy and safety of lenalidomide as maintenance therapy for high risk patients with chronic lymphocytic leukemia.

EUCTR2011-004698-98-ESDeutsche CLL-Studiengruppe, Innere Medizin I, Uniklinik Köln89

进行中（未招募）

1 期

EUCTR2014-003796-32-ITTeva Pharmaceutical Industries Ltd.14

进行中（未招募）

1 期

Study to evaluate the efficacy and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes

EUCTR2020-001926-71-DEDompe farmaceutici s.p.a.327

进行中（未招募）

1 期

A clinical study in adults with Growth Hormone Deficiency (GHD) who are not current users of growth hormone treatment to assess the efficacy, safety and tolerability of TV-1106 (experimental medicinal product)Growth hormone deficiencyMedDRA version: 17.1Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disorders

EUCTR2014-003796-32-DETeva Pharmaceutical Industries Ltd.150

进行中（未招募）

1 期

Study to evaluate the efficacy and the safety of ladaraxin in adult and adolescent patients withnew-onset type 1 diabetesew-onset Type 1 DiabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders

EUCTR2020-001926-71-SIDompe farmaceutici s.p.a.327